US vs EU: How can Europe translate home-grown innovation into biotech success?We have seen a boom in biotech initial public offerings over the last two years, but many of Share XUS vs EU: How can Europe translate home-grown innovation into biotech success?https://pharmaphorum.com/r-d/us-vs-eu-translate-home-grown-innovation-into-biotech-success/
Synthetic Control Arms – ambition to actionClinical trials are involved, expensive, and have been done largely the same way for decades but with today’s Share XSynthetic Control Arms – ambition to actionhttps://pharmaphorum.com/webinars/synthetic-control-arms-ambition-to-action/
Utilising real-time data to improve customer engagementOskar Möbert, Vice President OpenData Europe at Veeva Systems, tells us how they are reimagining customer reference data Share XUtilising real-time data to improve customer engagementhttps://pharmaphorum.com/sales-marketing/utilising-real-time-data-to-improve-customer-engagement/
Digital therapeutics: a new frontier of medicineThe area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is Share XDigital therapeutics: a new frontier of medicinehttps://pharmaphorum.com/digital/digital-therapeutics-a-new-frontier-of-medicine/
Understanding the prevention and treatment needs for cardiovascular diseaseWhat does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) Share XUnderstanding the prevention and treatment needs for cardiovascular diseasehttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/interview-with-benoit-creveau-head-of-commercial-operations-specialty-medicines-at-daiichi-sankyo-europe/
Chronic kidney disease: treating a silent killerIn November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of Share XChronic kidney disease: treating a silent killerhttps://pharmaphorum.com/patients/chronic-kidney-disease-treating-a-silent-killer/
Oslo Medicines Initiative asks how to balance innovation incentivisation with security of accessAccess to medicines is “one of the most challenging policy areas in every country in the European region” Share XOslo Medicines Initiative asks how to balance innovation incentivisation with security of accesshttps://pharmaphorum.com/views-analysis-market-access/oslo-medicines-initiative-balance-innovation-incentivisation-with-security-of-access/
Content metrics help generate compelling communicationCompanies seek efficiency and speed to market during the content creation process, review and approval cycles, and thus Share XContent metrics help generate compelling communicationhttps://pharmaphorum.com/sales-marketing/content-metrics-help-generate-compelling-communication/
The rise, acceleration and acceptance of telehealth adoption‘Healing at a distance’ is the literal meaning of telemedicine. According to the World Health Organization, it is Share XThe rise, acceleration and acceptance of telehealth adoptionhttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/the-rise-acceleration-and-acceptance-of-telehealth-adoption/
